Advanced cell therapy with low tissue factor loaded product NestaCell® does not confer thrombogenic risk for critically ill COVID-19 heparin-treated patients
使用低组织因子负载产品 NestaCell® 的先进细胞疗法不会给接受肝素治疗的重症 COVID-19 患者带来血栓形成风险。
期刊:Biomedicine & Pharmacotherapy
影响因子:7.5
doi:10.1016/j.biopha.2022.112920
Araldi, Rodrigo Pinheiro; Prezoto, Benedito Carlos; Gonzaga, Vivian; Policiquio, Bruna; Mendes, Thais Biude; D'Amélio, Fernanda; Vigerelli, Hugo; Viana, Mariana; Valverde, Cristiane Wenceslau; Pagani, Eduardo; Kerkis, Irina